| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/107424840300800206 |
| P698 | PubMed publication ID | 12808486 |
| P2093 | author name string | Moses Elisaf | |
| D P Mikhailidis | |||
| Angeliki Kostoula | |||
| Apostolos Achimastos | |||
| Eleni Bairaktari | |||
| Evangelos Rizos | |||
| Emanuel Ganotakis | |||
| George Hasiotis | |||
| P2860 | cites work | Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 |
| Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease | Q28192531 | ||
| Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients | Q28214265 | ||
| Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study | Q31829404 | ||
| Do HMG-CoA reductase inhibitors affect fibrinogen? | Q32052986 | ||
| Nebivolol in the management of essential hypertension: a review | Q33611957 | ||
| Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation | Q34373712 | ||
| Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. | Q34856889 | ||
| Clinical significance of pleiotropic effects of statins: lipid reduction and beyond | Q34946380 | ||
| Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis | Q34974714 | ||
| A dose-response study of atenolol in mild to moderate hypertension in general practice | Q40846337 | ||
| Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients | Q41875844 | ||
| Comparative study of HMG-CoA reductase inhibitors on fibrinogen | Q43545518 | ||
| Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels | Q43687595 | ||
| Effect of atorvastatin on serum uric acid levels | Q43733097 | ||
| A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration | Q43833293 | ||
| Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? | Q43913683 | ||
| The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). | Q43980848 | ||
| Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension | Q44165688 | ||
| Antihypertensive and Metabolic Effects of Single and Combined Atenolol Regimens | Q44889050 | ||
| Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation | Q46415777 | ||
| Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives. | Q51553248 | ||
| Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients. | Q51627282 | ||
| Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. | Q54061076 | ||
| P433 | issue | 2 | |
| P921 | main subject | patient | Q181600 |
| nebivolol | Q418130 | ||
| dyslipidemia | Q66291209 | ||
| P304 | page(s) | 127-134 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Journal of Cardiovascular Pharmacology and Therapeutics | Q1855644 |
| P1476 | title | The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study | |
| P478 | volume | 8 |
| Q49384173 | Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs |
| Q31149036 | Beta-blockers in the treatment of hypertension: new data, new directions |
| Q35157112 | Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension |
| Q38913816 | Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol |
| Q35107668 | Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases |
| Q46409073 | Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes |
| Q37826799 | Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers |
| Q37789491 | Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis |
| Q37762754 | Inflammation and therapy for hypertension. |
| Q28303617 | Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics |
| Q39699981 | Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. |
| Q38367410 | Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. |
| Q37031362 | Nebivolol in the treatment of chronic heart failure |
| Q36528216 | Nebivolol: a third-generation beta-adrenergic blocker |
| Q35846698 | Nebivolol: impact on cardiac and endothelial function and clinical utility. |
| Q37033656 | Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker |
| Q28238369 | Nebivolol: third-generation beta-blockade |
| Q37483065 | Nitric oxide mechanisms of nebivolol. |
| Q34142036 | Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. |
| Q36905034 | The vasodilatory beta-blockers |
| Q38200949 | β-blockers: a review of their pharmacological and physiological diversity in hypertension. |
Search more.